Page 61 - Product Testing News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS January 8, 2021 GMT NAARDEN, The Netherlands--(BUSINESS WIRE)--Jan 8, 2021-- Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the enrollment of the first participant for treatment with pridop...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 ProQR Therapeutics N.V.January 7, 2021 GMT Top-line results expected H1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V....

Press release content from Business Wire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation. Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy January 7, 2021 GMT NEW YORK--(BUSINESS WIRE)--Jan 7, 2021-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne mus...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Accesswire. The AP news staff was not involved in its creation. Najib Babul Discusses Erythropoietic Protoporphyria for a Severe Photodermatosis January 8, 2021 GMT CLARK COUNTY, NV / ACCESSWIRE / January 7, 2021 / Erythropoietic protoporphyria (EPP) is a devastating lifelong disorder characterized by dermal photosensitivity with only one recently approved treatment and very few evidence-based clinical management tools. Dr. Najib Babul, an experienced drug development...

Press release content from Business Wire. The AP news staff was not involved in its creation. Revance Provides Corporate Update and Anticipated Milestones for 2021 January 7, 2021 GMT NASHVILLE, Tenn.--(BUSINESS WIRE)--Jan 7, 2021-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided a corporate update, product pipeline timing and anticipated milestones for 2021. Financial Update and Key Launch Metrics: Pre...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Provides Preliminary 2020 Results and 2021 Outlook Amarin Corporation plcJanuary 7, 2021 GMT Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European Regulatory Review and Submission of China Regulatory Application for VASCEPA® (icosapent ethyl) Expected in Late January or February 2021 DUBLIN, Irela...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with ... Merus N.V.January 7, 2021 GMT UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. F...